Author:
Borg John-Joseph,Melchiorri Daniela,Sepodes Bruno,Caramella Carla M.,Tomino Carlo,Micallef Benjamin,Serracino-Inglott Anthony,Nistico Robert
Reference5 articles.
1. Challenges with advanced therapy medicinal products and how to meet them;Committee for Advanced Therapies (CAT);Nat. Rev. Drug Discov.,2010
2. Orphan drugs. EU regulations;Mariz;BMJ,2011
3. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products;Salmikangas;Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,2010
4. Establishing medical plausibility in the context of orphan medicines designation in the European Union;Tsigkos;Orphanet. J. Rare Dis.,2014
5. The European Parliament and Council. Regulation (EU) no 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. OJ. 2014; L 158: 1-76.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献